Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2003;41:33-36; doi:10.1136/dtb.2003.41533
Copyright © 2003 by the BMJ Publishing Group Ltd.

{blacktriangledown}Pimecrolimus cream for atopic dermatitis

Relevant BNF section: 13.5.3

{blacktriangledown}Pimecrolimus (pronounced pi-me-kro-ly-mus) cream (Elidel - Novartis) is a new topical immunosuppressant licensed for the treatment of patients aged 2 years or over with mild or moderate atopic dermatitis. It is the second topical treatment in this class, the first being {blacktriangledown}tacrolimus ointment (Protopic - Fujisawa) which we reviewed in October 2002.1 Pimecrolimus is the first such treatment to be licensed for first-line use in atopic dermatitis. It can be used either as short-term treatment for actively inflamed lesions, or as intermittent long-term treatment to prevent the progression of early symptoms and signs to flares.2 The company claims that "when used at the first sign of redness and itch" pimecrolimus cream is "the only treatment clinically proven to prevent progression to flare", and that many people using it have "eliminated or reduced steroid use". Here, we consider the place of pimecrolimus cream in the management of atopic dermatitis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Conroy, S (2004). NEW PRODUCTS FOR ECZEMA. EDUCATION AND PRACTICE 89: ep23-ep26 [Full Text]  
  • Williams, H. (2003). 1% Pimecrolimus Cream for Atopic Dermatitis--Reply. Arch Dermatol 139: 1370-1371 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Coming soon!

The DTB archive back to 1962, volume 1, issue 1 will soon be available.